BBA
CMPX icon

Baker Bros. Advisors’s Compass Therapeutics CMPX Stock Holding History

Baker Bros. Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-547,498
Closed -$1.04M – 89
2025
Q1 		$1.04M Sell
547,498
-1,010,132
-65% -$2.69M 0.01% 79
2024
Q4 		$2.26M Hold
1,557,630
– – 0.02% 83
2024
Q3 		$2.87M Hold
1,557,630
– – 0.03% 78
2024
Q2 		$1.56M Hold
1,557,630
– – 0.02% 84
2024
Q1 		$3.08M Hold
1,557,630
– – 0.04% 70
2023
Q4 		$2.43M Hold
1,557,630
– – 0.03% 71
2023
Q3 		$3.07M Hold
1,557,630
– – 0.02% 75
2023
Q2 		$4.95M Hold
1,557,630
– – 0.03% 71
2023
Q1 		$5.09M Hold
1,557,630
– – 0.03% 71
2022
Q4 		$7.83M Buy
+1,557,630
New +$6.21M 0.05% 68

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors's CMPX Position: Q2 2025 in Review

Baker Bros. Advisors sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 547,498 shares — an estimated $1.04M sold.

Baker Bros. Advisors first reported a position in CMPX in Q4 2022 and held it in 10 quarters. The position peaked at $7.83M in Q4 2022. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • Baker Bros. Advisors reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 547,498 Compass Therapeutics shares in Q2 2025, an estimated $1.04M.
  • Baker Bros. Advisors first reported a position in Compass Therapeutics in Q4 2022 and held it in 10 quarters.
  • Baker Bros. Advisors's Compass Therapeutics position peaked at $7.83M in Q4 2022.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.